Jeffrey Holford Recent News
Court Date For Litigation With Amgen And Other Expectations For AbbVie
Jefferies Sees Much Larger Market Opportunity For AstraZeneca, Upgrades To Buy
Jefferies Shares Pharma Stock Catalyst Outlook
Jefferies Updates Price Targets In Global Pharma, Sees 'Rich Catalyst Environment' Ahead
Amid Few Catalysts, Jefferies Downgrades AstraZeneca
Jefferies Says It's Buying Abbott Labs Stock On Emerging Market Growth, Valuation
New Report: Abbvie Is Jefferies' Top Global Pharma Stock
Could M&A Boost Pfizer More? Jefferies Thinks So
Jefferies Names AbbVie As Top Pharmaceutical Pick, Offers Alternative Choices
Jefferies Analyst Says AbbVie Hepatitis C Price-War Fears Overblown
A Pair Trade With Eli Lilly And Johnson & Johnson? Goldman Just Explained Why It's A Solid Idea
Deutsche Bank, Stifel Differ On Outlook For Eli Lilly
Jefferies Raises Zoetis Price Target, Says Consolidation Continues To Look Likely
UPDATE: Jefferies Lowers PT on Zoetis on Challenges Ahead
UPDATE: Jefferies Downgrades Pfizer on Challenges Ahead
UPDATE: Jefferies Lowers PT on Merck on Challenges Ahead
UPDATE: Jefferies Raises PT on Johnson & Johnson on Challenges Ahead
UPDATE: Jefferies Downgrades Bristol-Myers Squibb on Challenges Ahead
UPDATE: Jefferies Lowers PT on Pfizer Following Global Pharma Review
UPDATE: Jefferies Raises PT on Merck & Co. Following Global Pharma Review
UPDATE: Jefferies Lowers PT on Johnson & Johnson Following Global Pharma Review
UPDATE: Jefferies Lowers PT on Bristol-Myers Squibb Following Global Pharma Review
UPDATE: Jefferies Lowers PT on AbbVie on Attractive Entry Point Potential